精神分裂症和分裂情感障碍患者对 SARS-CoV-2 mRNA 疫苗的抗穗状病毒抗体反应

IF 3.7 Q2 IMMUNOLOGY
Katlyn Nemani , Livia De Picker , Faith Dickerson , Marion Leboyer , Michele Santacatterina , Fumika Ando , Gillian Capichioni , Thomas E. Smith , Jamie Kammer , Kawtar El Abdellati , Manuel Morrens , Violette Coppens , Emily Katsafanas , Andrea Origoni , Sabahat Khan , Kelly Rowe , R.Sarah Ziemann , Ryad Tamouza , Robert H. Yolken , Donald C. Goff
{"title":"精神分裂症和分裂情感障碍患者对 SARS-CoV-2 mRNA 疫苗的抗穗状病毒抗体反应","authors":"Katlyn Nemani ,&nbsp;Livia De Picker ,&nbsp;Faith Dickerson ,&nbsp;Marion Leboyer ,&nbsp;Michele Santacatterina ,&nbsp;Fumika Ando ,&nbsp;Gillian Capichioni ,&nbsp;Thomas E. Smith ,&nbsp;Jamie Kammer ,&nbsp;Kawtar El Abdellati ,&nbsp;Manuel Morrens ,&nbsp;Violette Coppens ,&nbsp;Emily Katsafanas ,&nbsp;Andrea Origoni ,&nbsp;Sabahat Khan ,&nbsp;Kelly Rowe ,&nbsp;R.Sarah Ziemann ,&nbsp;Ryad Tamouza ,&nbsp;Robert H. Yolken ,&nbsp;Donald C. Goff","doi":"10.1016/j.bbih.2024.100802","DOIUrl":null,"url":null,"abstract":"<div><h3>Importance</h3><p>Individuals with schizophrenia are at higher risk for severe COVID-19 illness and severe breakthrough infection following vaccination. It is unclear whether immune response to vaccination differs in this population.</p></div><div><h3>Objective</h3><p>To assess whether anti-SARS-CoV-2 spike antibody titers after vaccination differ in people with a diagnosis of schizophrenia or schizoaffective disorder (SZ) compared to controls without a psychiatric disorder.</p></div><div><h3>Design</h3><p>This cohort study assessed antibody response following the first and second dose of mRNA vaccines at longitudinal timepoints, up to 7 weeks following the first dose of vaccine.</p></div><div><h3>Setting</h3><p>A multi-center study including psychiatric healthcare settings in the United States and Europe.</p></div><div><h3>Participants</h3><p>205 adults with no history of COVID-19 infection, including 106 individuals with SZ and 99 controls without a psychiatric disorder, who received their first dose of SARS-CoV-2 mRNA vaccine between December 20, 2020 and May 27, 2021.</p></div><div><h3>Main outcomes and measures</h3><p>Mean SARS-CoV-2 anti-Spike IgG antibody levels within 7 weeks after the first dose of vaccination.</p></div><div><h3>Results</h3><p>A total of 205 individuals (mean [SD] age, 44.7 [12.0] years; 90 [43.9%] male) were included, of which 106 (51.7%) were diagnosed with SZ. SZ was associated with lower mean log antibody levels (−0.15; 95% CI, −0.27 to −0.03, <em>P</em> = 0.016) after adjusting for age, sex, body mass index, smoking, days since vaccination, and vaccine manufacturer. In secondary analyses of dose-specific responses, SZ was associated with a lower mean log antibody level after the second dose of vaccine (−0.23; 95% CI -0.39 to −0.06, <em>P</em> = 0.006), but not the first dose of vaccine (0.00; 95% CI -0.18— 0.19, <em>P</em> = 0.96).</p></div><div><h3>Conclusions and Relevance</h3><p>In this cohort study of individuals with SZ and a control group without psychiatric disorders, SZ was associated with lower SARS-CoV-2 anti-spike antibody levels following 2 doses of SARS-CoV-2 mRNA vaccination. This highlights the need for further studies assessing vaccine immunogenicity in individuals with schizophrenia.</p></div>","PeriodicalId":72454,"journal":{"name":"Brain, behavior, & immunity - health","volume":"38 ","pages":"Article 100802"},"PeriodicalIF":3.7000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666354624000802/pdfft?md5=be6f3f21a353c1ddec433f95d38a7fea&pid=1-s2.0-S2666354624000802-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Anti-spike antibody responses to SARS-CoV-2 mRNA vaccines in people with schizophrenia and schizoaffective disorder\",\"authors\":\"Katlyn Nemani ,&nbsp;Livia De Picker ,&nbsp;Faith Dickerson ,&nbsp;Marion Leboyer ,&nbsp;Michele Santacatterina ,&nbsp;Fumika Ando ,&nbsp;Gillian Capichioni ,&nbsp;Thomas E. Smith ,&nbsp;Jamie Kammer ,&nbsp;Kawtar El Abdellati ,&nbsp;Manuel Morrens ,&nbsp;Violette Coppens ,&nbsp;Emily Katsafanas ,&nbsp;Andrea Origoni ,&nbsp;Sabahat Khan ,&nbsp;Kelly Rowe ,&nbsp;R.Sarah Ziemann ,&nbsp;Ryad Tamouza ,&nbsp;Robert H. Yolken ,&nbsp;Donald C. Goff\",\"doi\":\"10.1016/j.bbih.2024.100802\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Importance</h3><p>Individuals with schizophrenia are at higher risk for severe COVID-19 illness and severe breakthrough infection following vaccination. It is unclear whether immune response to vaccination differs in this population.</p></div><div><h3>Objective</h3><p>To assess whether anti-SARS-CoV-2 spike antibody titers after vaccination differ in people with a diagnosis of schizophrenia or schizoaffective disorder (SZ) compared to controls without a psychiatric disorder.</p></div><div><h3>Design</h3><p>This cohort study assessed antibody response following the first and second dose of mRNA vaccines at longitudinal timepoints, up to 7 weeks following the first dose of vaccine.</p></div><div><h3>Setting</h3><p>A multi-center study including psychiatric healthcare settings in the United States and Europe.</p></div><div><h3>Participants</h3><p>205 adults with no history of COVID-19 infection, including 106 individuals with SZ and 99 controls without a psychiatric disorder, who received their first dose of SARS-CoV-2 mRNA vaccine between December 20, 2020 and May 27, 2021.</p></div><div><h3>Main outcomes and measures</h3><p>Mean SARS-CoV-2 anti-Spike IgG antibody levels within 7 weeks after the first dose of vaccination.</p></div><div><h3>Results</h3><p>A total of 205 individuals (mean [SD] age, 44.7 [12.0] years; 90 [43.9%] male) were included, of which 106 (51.7%) were diagnosed with SZ. SZ was associated with lower mean log antibody levels (−0.15; 95% CI, −0.27 to −0.03, <em>P</em> = 0.016) after adjusting for age, sex, body mass index, smoking, days since vaccination, and vaccine manufacturer. In secondary analyses of dose-specific responses, SZ was associated with a lower mean log antibody level after the second dose of vaccine (−0.23; 95% CI -0.39 to −0.06, <em>P</em> = 0.006), but not the first dose of vaccine (0.00; 95% CI -0.18— 0.19, <em>P</em> = 0.96).</p></div><div><h3>Conclusions and Relevance</h3><p>In this cohort study of individuals with SZ and a control group without psychiatric disorders, SZ was associated with lower SARS-CoV-2 anti-spike antibody levels following 2 doses of SARS-CoV-2 mRNA vaccination. This highlights the need for further studies assessing vaccine immunogenicity in individuals with schizophrenia.</p></div>\",\"PeriodicalId\":72454,\"journal\":{\"name\":\"Brain, behavior, & immunity - health\",\"volume\":\"38 \",\"pages\":\"Article 100802\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666354624000802/pdfft?md5=be6f3f21a353c1ddec433f95d38a7fea&pid=1-s2.0-S2666354624000802-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brain, behavior, & immunity - health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666354624000802\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain, behavior, & immunity - health","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666354624000802","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

重要性精神分裂症患者在接种疫苗后发生严重 COVID-19 疾病和严重突破性感染的风险较高。目的评估精神分裂症或分裂情感性障碍(SZ)患者接种疫苗后的抗SARS-CoV-2尖峰抗体滴度与无精神障碍的对照组相比是否存在差异。设计这项队列研究评估了接种第一剂和第二剂 mRNA 疫苗后抗体反应的纵向时间点,最长时间为接种第一剂疫苗后 7 周。参与者205名无COVID-19感染史的成年人,包括106名SZ患者和99名无精神障碍的对照者,他们在2020年12月20日至2021年5月27日期间接种了第一剂SARS-CoV-2 mRNA疫苗。结果共纳入 205 人(平均 [SD] 年龄 44.7 [12.0] 岁;男性 90 [43.9%]),其中 106 人(51.7%)被诊断为 SZ。在对年龄、性别、体重指数、吸烟、接种天数和疫苗生产商进行调整后,SZ 与较低的平均对数抗体水平相关(-0.15;95% CI,-0.27 至 -0.03,P = 0.016)。在剂量特异性反应的二次分析中,SZ 与第二剂疫苗后较低的平均对数抗体水平相关(-0.23;95% CI -0.39 至 -0.06,P = 0.006),但与第一剂疫苗无关(0.00;95% CI -0.18- 0.结论和相关性在这项针对 SZ 患者和无精神障碍对照组的队列研究中,SZ 与接种 2 剂 SARS-CoV-2 mRNA 疫苗后较低的 SARS-CoV-2 抗尖峰抗体水平有关。这强调了进一步研究评估精神分裂症患者疫苗免疫原性的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Anti-spike antibody responses to SARS-CoV-2 mRNA vaccines in people with schizophrenia and schizoaffective disorder

Importance

Individuals with schizophrenia are at higher risk for severe COVID-19 illness and severe breakthrough infection following vaccination. It is unclear whether immune response to vaccination differs in this population.

Objective

To assess whether anti-SARS-CoV-2 spike antibody titers after vaccination differ in people with a diagnosis of schizophrenia or schizoaffective disorder (SZ) compared to controls without a psychiatric disorder.

Design

This cohort study assessed antibody response following the first and second dose of mRNA vaccines at longitudinal timepoints, up to 7 weeks following the first dose of vaccine.

Setting

A multi-center study including psychiatric healthcare settings in the United States and Europe.

Participants

205 adults with no history of COVID-19 infection, including 106 individuals with SZ and 99 controls without a psychiatric disorder, who received their first dose of SARS-CoV-2 mRNA vaccine between December 20, 2020 and May 27, 2021.

Main outcomes and measures

Mean SARS-CoV-2 anti-Spike IgG antibody levels within 7 weeks after the first dose of vaccination.

Results

A total of 205 individuals (mean [SD] age, 44.7 [12.0] years; 90 [43.9%] male) were included, of which 106 (51.7%) were diagnosed with SZ. SZ was associated with lower mean log antibody levels (−0.15; 95% CI, −0.27 to −0.03, P = 0.016) after adjusting for age, sex, body mass index, smoking, days since vaccination, and vaccine manufacturer. In secondary analyses of dose-specific responses, SZ was associated with a lower mean log antibody level after the second dose of vaccine (−0.23; 95% CI -0.39 to −0.06, P = 0.006), but not the first dose of vaccine (0.00; 95% CI -0.18— 0.19, P = 0.96).

Conclusions and Relevance

In this cohort study of individuals with SZ and a control group without psychiatric disorders, SZ was associated with lower SARS-CoV-2 anti-spike antibody levels following 2 doses of SARS-CoV-2 mRNA vaccination. This highlights the need for further studies assessing vaccine immunogenicity in individuals with schizophrenia.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Brain, behavior, & immunity - health
Brain, behavior, & immunity - health Biological Psychiatry, Behavioral Neuroscience
CiteScore
8.50
自引率
0.00%
发文量
0
审稿时长
97 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信